UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Essential Role for LEDGF/p75 in HIV Integration

Science (American Association for the Advancement of Science), 2006-10, Vol.314 (5798), p.461-464

2006

Volltextzugriff (PDF)

TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism

Journal of virology, 2014-09, Vol.88 (17), p.9704-9717

2014

Volltextzugriff (PDF)

High-throughput screening for growth inhibitors using a yeast model of familial paraganglioma

PloS one, 2013-02, Vol.8 (2), p.e56827

2013

Volltextzugriff (PDF)

Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA

Hematology, Transfusion and Cell Therapy, 2022-07, Vol.44 (3), p.358-364

2022

Volltextzugriff (PDF)

LEDGF/p75 Determines Cellular Trafficking of Diverse Lentiviral but Not Murine Oncoretroviral Integrase Proteins and Is a Component of Functional Lentiviral Preintegration Complexes

Journal of Virology, 2004-09, Vol.78 (17), p.9524-9537

2004

Volltextzugriff (PDF)

The HIV-1 Central Polypurine Tract Functions as a Second Line of Defense against APOBEC3G/F

Journal of Virology, 2010-11, Vol.84 (22), p.11981-11993

2010

Volltextzugriff (PDF)

LEDGF Dominant Interference Proteins Demonstrate Prenuclear Exposure of HIV-1 Integrase and Synergize with LEDGF Depletion To Destroy Viral Infectivity

Journal of Virology, 2011-04, Vol.85 (7), p.3570-3583

2011

Volltextzugriff (PDF)

Restriction of Feline Immunodeficiency Virus by Ref1, Lv1, and Primate TRIM5α Proteins

Journal of Virology, 2005-12, Vol.79 (24), p.15175-15188

2005

Volltextzugriff (PDF)

Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration

Retrovirology, 2015-03, Vol.12 (1), p.24-24, Article 24

2015

Volltextzugriff (PDF)

Feline immunodeficiency virus-based lentiviral vectors

Cold Spring Harbor protocols, 2012-01, Vol.2012 (1), p.71

2012

Volltextzugriff (PDF)

Pre-clinical activity of BET protein antagonist-based combinations against ibrutinib-sensitive or -resistant human Mantle Cell Lymphoma cells

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.S64-S64

2015

Volltextzugriff (PDF)

Production, harvest, and concentration of feline immunodeficiency virus-based lentiviral vector from cells grown in CF10 or CF2 devices

Cold Spring Harbor protocols, 2012-01, Vol.2012 (1), p.118

2012

Volltextzugriff (PDF)

Production and harvest of feline immunodeficiency virus-based lentiviral vector from cells grown in T75 tissue-culture flasks

Cold Spring Harbor protocols, 2012-01, Vol.2012 (1), p.124

2012

Volltextzugriff (PDF)

Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.6572-6572

2024

Volltextzugriff (PDF)

Targeting nuclear [beta]-catenin as therapy for post-myeloproliferative neoplasm secondary AML

Leukemia, 2019-06, Vol.33 (6), p.1373

2019

Volltextzugriff (PDF)

Abstract 1071: Targeted therapy evaluation in novel pre-clinical in vitro and in vivo models of Richter transformation

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1071-1071

2019

Volltextzugriff (PDF)

Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3836-3836

2019

Volltextzugriff (PDF)

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Blood, 2019-11, Vol.134 (Supplement_1), p.538-538

2019

Volltextzugriff (PDF)

Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3036-3036

2019

Volltextzugriff (PDF)

Feline Immunodeficiency Virus Gag Is a Nuclear Shuttling Protein

Journal of virology, 2013-02, Vol.87 (3), p.1922-1922

2013

Volltextzugriff (PDF)

Abstract 802: Targeted inhibition of KDM1A and BET proteins or DNMT1 exerts synergistic lethal activity against human AML blast progenitor cells

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.802-802

2018

Volltextzugriff (PDF)

Abstract 3884: Novel RUNX1 targeted therapy for AML expressing mutant RUNX1

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3884-3884

2018

Volltextzugriff (PDF)

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Blood, 2017-12, Vol.130, p.1265-1265

2017

Volltextzugriff (PDF)

Feline Immunodeficiency Virus-Based Lentiviral Vectors: Figure 1

Cold Spring Harbor protocols, 2012-01, Vol.2012 (1), p.pdb.ip067579

2012

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(38)
Publisher or Other Site
(23)
MEDLINE
(11)
Journals@Ovid Ovid Full Text
(9)
Ingenta
(6)
Elsevier ScienceDirect Journals Complete
(6)
IngentaConnect Journals
(5)
American Association for the Advancement of Science
(1)
JSTOR
(1)
Nexis Uni
(1)
Nature
(1)
Springer Journals
(1)

7 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Essential Role for LEDGF/p75 in HIV Integration

TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

High-throughput screening for growth inhibitors using a yeast model of familial paraganglioma

Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA

LEDGF/p75 Determines Cellular Trafficking of Diverse Lentiviral but Not Murine Oncoretroviral Integrase Proteins and Is a Component of Functional Lentiviral Preintegration Complexes

The HIV-1 Central Polypurine Tract Functions as a Second Line of Defense against APOBEC3G/F

LEDGF Dominant Interference Proteins Demonstrate Prenuclear Exposure of HIV-1 Integrase and Synergize with LEDGF Depletion To Destroy Viral Infectivity

Restriction of Feline Immunodeficiency Virus by Ref1, Lv1, and Primate TRIM5α Proteins

Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration

Feline immunodeficiency virus-based lentiviral vectors

Pre-clinical activity of BET protein antagonist-based combinations against ibrutinib-sensitive or -resistant human Mantle Cell Lymphoma cells

Production, harvest, and concentration of feline immunodeficiency virus-based lentiviral vector from cells grown in CF10 or CF2 devices

Production and harvest of feline immunodeficiency virus-based lentiviral vector from cells grown in T75 tissue-culture flasks

Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF)

Targeting nuclear [beta]-catenin as therapy for post-myeloproliferative neoplasm secondary AML

Abstract 1071: Targeted therapy evaluation in novel pre-clinical in vitro and in vivo models of Richter transformation

Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor

Feline Immunodeficiency Virus Gag Is a Nuclear Shuttling Protein

Abstract 802: Targeted inhibition of KDM1A and BET proteins or DNMT1 exerts synergistic lethal activity against human AML blast progenitor cells

Abstract 3884: Novel RUNX1 targeted therapy for AML expressing mutant RUNX1

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Feline Immunodeficiency Virus-Based Lentiviral Vectors: Figure 1

Aktive Filter

Suchergebnisse filtern